The disclosure relates, in some aspects, to compositions and methods fortreatment of diseases associated with aberrantlysosomal function, for example Parkinson's disease (PD) and Gaucher disease.In some embodiments, the disclosure providesexpression constructs comprising a transgene encoding beta-Glucocerebrosidase(GBA) or a portion thereof alone or in combinationwith one or more PD-associated genes. In some embodiments, the disclosureprovides methods of Parkinson's disease byadministering such expression constructs to a subject in need thereof.
